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ABSTRACT 
Objective: India accounts for about one-fourth of the global TB burden. WHO TB statistics for India for 2018 gives an estimated incidence fig. of 
2.69 million cases (199 per one lakh population). Drug-induced Hepatotoxicity is responsible for significant morbidity and mortality of the TB 
patient if these drugs continued after symptoms of hepatotoxicity develop. Whether the hepatotoxicity is due to individual drugs or due to additive 
effects is still unclear. The management therapy for TB patients with anti-TB DIH is imperative to ensure successful TB treatment and not 
recurrence DIH. Aim of the current study is to find out the pattern of Liver enzyme raised after antitubercular therapy in the tribal population of 
Koraput district where different phylogenetic populations reside where clinically it was observed by the physician little early onset of 
hepatotoxicity than national and international data. 
Methods: A prospective study was done after clearance from the Institutional Ethical Committee, Saheed Laxman Nayak Medical College, Koraput, 
from January 2019 to December 2019. Patients with>15 y of age with pulmonary and extrapulmonary tuberculosis with normal liver enzymes were 
included. Patients having abnormal liver enzymes before treatment, seropositive TB patients with human immunodeficiency virus infection, 
pregnant ladies and children<15 y of age were excluded. 
Results: Out of 922 patients in total; 4.78% (44) tuberculosis patients developed anti TB DIH. 68.18% (30) patients are below 50 y of age and 31.82% 
(14) are above 50 y of age group among TB patients with DIH. Age has no statistically significant influence on the occurrence of anti-TB DIH, but there is 
a statistically significant influence of sex on the occurrence of anti TB DIH. The mean occurrence of anti TB DIH is 18±18.16 d. One case of anti TB DIH 
patients shows signs and symptoms as early as on day 6th. The commonest symptoms are nausea and vomiting in 64% of patients who developed DIH. 
Interruption of ATT after DIH occurred in 79.54% of patients with recurrence in only 9.9% of patients after the reintroduction of ATT.  
Conclusion: Anti TB DIH mostly occurred between 7-28 d of starting the ATT in this geographical region. The duration of the anti TB ATT regimen 
is prolonged due to DIH. We recommend that all patients should have LTs 2 w after starting ATT, even if asymptomatic. 
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INTRODUCTION 
Tuberculosis (TB) continues to remain as one of the most significant 
infectious diseases across much of the world. It carries an alarming 
socioeconomic burden on the individual and society. Tuberculosis 
remains an important cause of ill health and is one of the top 10 
causes of death universally. An estimated 10.0 million with a range 
of 9.0–11.1 million people fell ill with tuberculosis in 2018 [1]. In 
2018, geographically, most tuberculosis cases were in the World 
Health Organization (WHO) regions of South-East Asia (44%), Africa 
(24%) and the Western Pacific (18%). India (27%), China (9%), 
Indonesia (8%), the Philippines (6%), Pakistan (6%), Nigeria (4%), 
Bangladesh (4%), and South Africa (3%) accounted for two-thirds of 
the universal total [1]. India accounts for about one-fourth of the 
global TB burden [2]. It is estimated that about 40% of the Indian 
population is infected with Mycobacterium tuberculosis; the vast 
majority of those have latent tuberculosis rather than the disease. 
For 2018, WHO TB statistics for India give an estimated incidence 
fig. of 2.69 million TB cases (199 per one lakh population) [3]. 50303 
and 71131 patients are notified with TB in both the public and 
private sector in ODISHA in 2018 and 2017 respectively [3]. 
Revised National Tuberculosis Control Programme (RNTCP) Anti 
Tubercular Therapy (ATT) is the only cost-effective strategy to treat 
pulmonary tuberculosis as recommended by WHO. Drug-Induced 
Hepatotoxicity (DIH) is important and commonly occurring adverse 
drug reaction (ADR) with Isoniazid, Rifampicin, and Pyraniazide. 
Due to anti TB drug treatment, the reported incidence of DIH due to 
anti-TB standards varied between 2.0% and 28.0% depending on 
population differences and the definition of DIH [4]. A study in India 
showed that disturbed liver transaminases (33.33%) were common 
in ADR observed from first-line anti-TB drugs. Nausea and vomiting, 
hepatitis, rash, headache, constipation, fever, flu-like syndrome, 
blurred vision and optic neuritis, metabolic disturbances including 
hyperglycemia, and diarrhea are the other ADRs included [5]. The 
percentage of patients with single and more than one ADR from 
first-line anti-TB drugs were 24.09% and 75.9%, respectively, as 
shown by another study [4]. A higher risk of hepatotoxicity has been 
reported in Indian patients (6-9) than in their Western counterparts 
(10-12). The causes for this higher rate of hepatotoxicity in Indian 
patients are indistinct. Anti TB DIH accounts for 7% of reported drug 
adverse effects, 2% of jaundice in hospitals, and approximately 30% 
of fulminant liver failure [13, 14]. 
Dissimilar suggestions have been made for monitoring liver tests 
(LTs) in patients on ATT by the American Thoracic Society (ATS) 
[15], the British Thoracic Society [16], and the European Respiratory 
Society (ERS) [17] with some favoring a risk factor-based approach. 
Singanayagam et al. compared the two approaches, judging in 
support of universal testing 2 w into treatment [18].  
The Drug-Induced Liver Injury (DILI) Expert Working Group [19] 
and DILIGEN study [20] use criteria based on ALT, ALP, and 
bilirubin to guide the stoppage of ATT. All expert recommendations 
comprise treatment cessation at ALT>5x Upper Limit of Normal 
(ULN) or if the patient is icteric; ATS recommends cessation if ALT is 
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3-5xULN and the patient reports symptoms including nausea, 
anorexia, vomiting, abdominal pain, and jaundice. Each advisory 
body has recommendations for treatment re-introduction when LTs 
have normalized; these either opine sequential re-introduction with 
incremental dose increase or re-introduction at full dosage [15-17].  
Anti-tuberculosis drug-induced hepatotoxicity (anti-TB-DIH) may be 
a consequence of the direct toxicity of the primary compound, a 
metabolite, or from an immunologically mediated response, 
affecting hepatocytes, biliary epithelial cells, and/or liver 
vasculature [15, 21]. Most types of anti-TB-DIH are attributable to 
metabolic idiosyncrasy due to the metabolites released or 
accumulated during the metabolic course. These hypersensitivity or 
metabolic reactions happen largely independent of the dose [22]. 
The pathogenesis of DIH caused by Isoniazid is not well understood 
[23]. Hepatocyte necrosis, ballooning degeneration, and 
inflammatory infiltrate suggest dose-related toxicity [24]. Whether 
the hepatotoxicity is due to individual drugs or due to additive 
effects is still unclear. 
DIH diminishes the efficiency of anti-TB management, may lead to 
non-adherence and can cause treatment failure, recurrence, or drug 
resistance [25]. DIH is responsible for major morbidity and 
mortality of tuberculosis patients if these therapies continued after 
symptoms of hepatotoxicity manifest [26]. The management therapy 
for TB patients with anti TB DIH is imperative to ensure successful 
TB treatment and not recurrence DIH.  
AIM OF THE STUDY 
So the aim of current study is to find out the pattern of Liver enzyme 
raised after ATT in the tribal population of Koraput district where 
different phylogenetic populations reside where clinically it was 
observed by the physician little early onset of hepatotoxicity than 
national and international data. 
MATERIALS AND METHODS 
A prospective study was done after clearance from Institutional 
Ethical Committee, Saheed Laxman Nayak Medical College, Koraput 
from January 2019 to December 2019. Patients’ data were collected 
from the Department of TB and Chest and Medical Record 
Department SLNMCH. Patients’ demographic data, co-morbidities, 
addictions, medications, signs and symptoms, details of ATT, time of 
DIH onset from the start of ATT, duration of withdrawal of ATT, 
timing of the reintroduction of ATT were collected. Investigations 
details like sputum for AFB, CBNAAT, Chest X-ray, Urea, Creatinine, 
Liver enzymes, Serum bilirubin, HIV, Hepatitis, CBC, FBS, HbA1c data 
also collected for evaluation and analysis. During the beginning of 
treatment for tuberculosis, those patients who had no abnormal 
liver functions were taken as study population, and patients with 
active TB without DIH were considered as control. DIH case was 
defined as per DILI Expert working Group and DILIGEN CRITERIA. 
Monitoring of patients, who started ATT, was done every 7 d by 
evaluating Liver Function Tests and comparing with baseline values 
before treatment in those patients who developed symptoms of liver 
injury. If ATT was more than 3 times Upper Normal Limits with 
symptoms and 5 times ULN without symptoms, ATT was 
discontinued. In the case of severe tuberculosis patients, modified 
ATT regimens were continued. After Liver enzymes come to normal 
after treatment again ATT started under close supervision and 
monitoring of liver enzymes by TB and Chest Physician. 
Inclusion criteria 
• Patients with>15 y of age. 
• Those patients with pulmonary and extrapulmonary tuberculosis 
with normal liver enzymes. 
Exclusion criteria 
• Patients having abnormal liver enzymes before treatment. 
• TB patients with human immunodeficiency virus infection.  
• Pregnant ladies and children<15 y of age. 
Statistical analysis 
The statistical analysis was done using the Statistical Package for Social 
Sciences (SPSS) version 21.0. Discrete variables were presented as 
frequency and percentages. Continuous variables were presented as 
means and standard deviation (SD) for unpaired data; a Student t-test 
was used to compare mean values (for two groups). A Chi-square test 
was used to determine the significant associations between categorical 
variables. P-value<0.05* was considered statistically significant and P-
value<0.001** was considered statistically very significant. 
RESULTS 
During the study period, a total of 922 patients were diagnosed with 
tuberculosis and given ATT in SLNMCH. Out of which 51.41% (474) 
cases were pulmonary tuberculosis and 46.75% (431) cases were 
extrapulmonary tuberculosis; the rest 17 cases had no data about 
the site of the lesion. Out of 922 cases with tuberculosis, we included 
44 tuberculosis patients with anti TB DIH (4.78%) in our study that 
fulfills inclusion and exclusion criteria. They were compared with 44 
TB patients without anti TB DIH who were taken as controls. 
 
Table 1: Age distribution 
Age  TB patients with DIH (n=44) TB patients without DIH (n=44) P-value 
f % f % 
<50 y 30 68.18% 32 72.73% P = 0.815 
>50 y 14 31.82% 12 27.27% 
 
Table 1 shows in our study population, 68.18% (30) patients are 
below 50 y of age and 31.82% (14) are above 50 y of age group 
among TB patients with DIH. Age has no statistically significant (p = 
0.815) influence on the occurrence of anti-TB DIH [table 1], but 
there is statistically significant (p = 0.027)* influence of sex on 
occurrence of anti TB DILI [table 2]. Table 2 show M: F ratio among 
TB patients without DIH is 3: 1 whereas it is 1: 1 among TB patients 
with DIH. 
 
Table 2: Sex distribution 
Sex 
 
TB patients with DIH (n=44) TB patients without DIH (n=44) P-value 
f % f % 
Male 22 50% 33 75% P = 0.027* 
Female 22 50% 11 25% 
 
One case of anti TB DIH patients shows signs and symptoms as early 
as on day 6th and confirmed by lab findings on day 7th; and the last 
case or delayed case detected on the 42nd day of starting 
antitubercular drugs. The mean occurrence of anti TB DIH is 
18±18.16 d [table 3]. The number of TB patients who developed DIH 
between 7th to 28th days is more (62%). 
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Table 3: Time of onset in tuberculosis patients with DIH 
Onset of DIH  
Min-max days 6th–42nd day 
mean±SD 18±18.16 d 
AST, ALT and total bilirubin tests have been conducted in all TB patients with anti-tubercular drugs. Initially, there is no significant difference in 
AST, ALT, and total bilirubin on day 0. 
 
Table 4: Comparison of laboratory parameters of TB patients with anti TB DIH and without anti TB DIH 
Laboratory parameters TB patients with DIH (n=44) TB patients without DIH (n=44) P-value 
In mean+SD In mean+SD 
Hemoglobin (gm/dl) 10.09±1.32 11.09±1.62 0.002* 
Total bilirubin (mg/dl) 1.87±1.25 0.94±0.35 <0.001** 
Aspartate aminotransferase/AST(IU/l) 246.97±22.45 40.38±12.37 <0.001** 
Alanine aminotransferase/ALT(IU/l) 152.53±11.21 41.64±13.52 <0.001** 
Comparison between laboratory parameters of TB patients with anti-TB DIH and without anti TB DIH showed a statistically significant difference. 
Values are expressed as mean+SD. 
 
Table 4 shows liver function tests conducted for tuberculosis patients 
at the beginning of diagnosis of DIH. The mean test result for 
hemoglobin, total bilirubin, AST, and ALT is 10.09±1.32 gm/dl, 
1.87±1.25 mg/dl, 246.97±22.45 IU/l, and 152.53±11.21 IU/l, 
respectively; which are found to be statistically very significant when 
compared with the same parameters in TB patients without DIH. 
  
Table 5: Impact of anti TB DIH on TB treatment of the patients (N=44) 
Impact of anti TB DIH Number of anti-TB DIH patients (N=44) 
F % 
Stop all anti-tubercular drugs/interruption of ATT after DIH 35 79.54% 
Modified ATT/Substitution therapy (Streptomycin, Levofloxacin, Ethambutol) 8 18.18% 
No change in ATT/Treatment continue 1 2.27% 
Recurrence anti TB DIH 4 9.09% 
 
After diagnosis of anti-TB DIH, in 35 (79.54%) patients, all anti-
tubercular drugs are stopped; in 8 (18.18%) patients, the 
substitution therapy with Streptomycin, Levofloxacin and 
Ethambutol (modified ATT) are given after withdrawn of anti-TB 
therapy [table 5]. In 1 (2.27%) patient; there was no change in anti 
TB regimen and the treatment with ATT was continued. After 
treatment with hepatoprotective drugs in those 35 patients in whom 
ATT was stopped, there was an improvement in liver enzymes and 
signs and symptoms in all 35 patients after one month. But, in 4 
(9.9%) patients, recurrence of anti TB DIH occurs.  
DISCUSSION 
During the study period, out of 922 patients in total; 51.41% (474) 
cases were pulmonary tuberculosis and 46.75% (431) cases were 
extrapulmonary tuberculosis. Out of which, we included 44 
tuberculosis patients with anti TB DIH (4.78%) in our study that 
fulfills inclusion and exclusion criteria. Alu Abbra et al. study found 
the onset of anti TB DIH in 6.9% of tuberculosis patients [27]. 
Age has no statistically significant (p>0.05) influence on the 
occurrence of anti-TB DIH [table 1], but there is statistically 
significant (p<0.05) influence of sex on the occurrence of anti TB 
DIH [table 2] in our study. In Gronhagen et al. study, female was a 
risk factor for hepatotoxicity [28]. Maria et al. study showed that age 
and sex not statistically significant influences on the occurrence of 
anti-TB DIH [29]. With a different result, Buntoro et al. study 
showed that sex did not affect the increase in ALT level but age had 
an effect on the increase in ALT level in TB patients who were 
treated with first-line anti-TB drugs [30]. 
In our study, we found that lower Hb, low body weight and alcohol 
consumption has a higher rise in liver enzymes. Gronhagen et al. 
study also found high alcohol intake as a risk factor for 
hepatotoxicity [28].  
The commonest symptoms are nausea and vomiting in 64% of 
patients who developed DIH. Jaundice was found in 28% of the 
patients who developed DIH. 55% had digestive symptoms and 
jaundice was the presenting complaint in 10% of patients in the 
Black et al. study [24]. 
If AST or ALT is more than 5 times the ULN value with or without 
symptoms and>3 times plus jaundice or hepatitis the ATT should be 
discontinued [15, 16, and 31]. In our study, anti TB drugs were 
discontinued in 79.54% of patients as they meet the above-
mentioned criteria. In 18.18% of patients, the increase in AST, ALT is 
not more than 5 times the ULN but in between 2 to 5 times without 
jaundice or hepatitis. So in these 8 patients, we substitute the 
recommended ATT with modified ATT Streptomycin, Levofloxacin, 
and Ethambutol. In one patient (2.27%) there is no significant 
increase in liver enzymes so ATT is continued but under 
observation. 9.09% had a recurrence of DIH. These findings were 
very much similar to Maria et al. study, which found interruption in 
78.9%, substitution therapy in 15.8%, no change of treatment in 
2.27%, and recurrence in 11.4% of anti TB DIH patients [29]. 
In our study, 62% of anti TB DIH occurred between 7th to 28th days 
of starting ATT which is quite earlier than other studies. In Alu 
Abbra et al. study, the onset of DIH in 53% of patients was within 2 
w [27]. The median time to DIH of 18+18.16 d is comparable with 
the Singanayagam et al. study and Alu Abbra et al. study [18, 27] and 
indicates to us that all patients should have LTs 2 w after starting 
ATT, even if asymptomatic. The improvement in liver enzymes 
started from day 10th onwards up to day 25th of withdrawal of ATT 
and after starting the hepatoprotective drug.  
CONCLUSION 
Anti TB DIH mostly occurred between 7-28 d of starting the ATT in 
this geographical region with a median time to DIH of (18+18.16). 
Maximum patients who developed DIH respond to the 
hepatoprotective drug with ATT withdrawal of one month. In only 
9.9% of patients, there is a recurrence of hepatotoxicity after 
reintroduction of ATT. The rest of the anti-TB DIH patients 
completed their anti TB treatment after recovery of one month 
successfully. But the duration of the anti TB ATT regimen is 
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prolonged due to DIH. We recommend that all patients should have 
LTs 2 w after starting ATT, even if asymptomatic. 
LIMITATIONS OF THE STUDY 
A more extensive study, including large number of patients and for 
longer period; with an appropriate clinical trial is required to arrive 
at a firm conclusion. 
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